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Abstract—The efficacy of drug treatments depends on how
tightly small molecules bind to their target proteins. Quanti-
fying the strength of these interactions (the so called ‘binding
affinity’) is a grand challenge of computational chemistry, sur-
mounting which could revolutionize drug design and provide the
platform for patient specific medicine. Recently, evidence from
blind challenge predictions and retrospective validation studies
has suggested that molecular dynamics (MD) can now achieve
useful predictive accuracy (≤ 1 kcal/mol) This accuracy is suffi-
cient to greatly accelerate hit to lead and lead optimization.
To translate these advances in predictive accuracy so as to
impact clinical and/or industrial decision making requires that
binding free energy results must be turned around in timescales
of hours without loss of accuracy. This demands advances in al-
gorithms, scalable software systems, and intelligent and efficient
utilization of supercomputing resources. Specifically, it necessi-
tates refining algorithms and developing technologies to marshal
huge simulation campaigns.
This work is motivated by the real world problem of provid-
ing insight from drug candidate data on a time scale that is as
short as possible. Specifically, we reproduce results from a col-
laborative project between UCL and GlaxoSmithKline to study
a congeneric series of drug candidates binding to the BRD4 pro-
tein – inhibitors of which have shown promising preclinical ef-
ficacy in pathologies ranging from cancer to inflammation. We
demonstrate the use of a framework called HTBAC, designed to
support the aforementioned requirements of accurate and rapid
drug binding affinity calculations. HTBAC facilitates the execu-
tion of the numbers of simulations while supporting the adaptive
execution of algorithms. Furthermore, HTBAC enables the se-
lection of simulation parameters during runtime which can, in
principle, optimize the use of computational resources whilst pro-
ducing results within a target uncertainty.
I. SCIENTIFIC MOTIVATION
Bromodomain-containing proteins, and in particular the four
members of the BET (bromodomain and extra terminal do-
main) family, are currently a major focus of research in the
pharmaceutical industry. Small molecule inhibitors of these
proteins have shown promising preclinical efficacy in patholo-
gies ranging from cancer to inflammation. Indeed, several
compounds are progressing through early stage clinical trials
and are showing exciting early results [1]. One of the most
extensively studied targets in this family is the first bromod-
Fig. 1. (L) Cartoon representation of the BRD4 bound to an inhibitor shown
in chemical representation (based on PDB:4BJX). (R) Ligand in cartoon rep-
resentation with the tetrahydroquinoline scaffold highlighted in magenta. The
regions which are modified between ligands investigated are labelled 1 to 4.
omain of bromodomain-containing protein 4 (BRD4-BD1) for
which extensive crystallographic and ligand binding data are
available [2].
We have investigated a congeneric series of ligands binding
to BRD4-BD1 (we shall from now on refer to this are simply
BRD4). This was performed in the context of a blind test of
the protocols in collaboration with GlaxoSmithKline [3]. The
goal was to benchmark free energy calculations in a realistic
drug discovery scenario. In the original study, we investigated
chemical structures of 16 ligands based on a single tetrahy-
droquinoline (THQ) scaffold. These studies employed two dif-
ferent algorithms (simulation protocols), known as TIES and
ESMACS [4], both based on multiple simulations of the same
system. Drug design projects have limited resources, so ini-
tially large numbers of compounds must be cheaply screened
to eliminate poor binders (using ESMACS), before more ac-
curate methods (such as TIES) are needed as good binders are
refined and improved.
In order to support such investigations, in addition to scale,
the protocols must be executed to utilize flexible resource man-
agement schemes where based upon intermediate results at
runtime, resources can be (re-)allocated between instances of
different protocols or systems, for example, when one calcu-
lation has converged whilst another has not. Such adaptabil-
ity makes it easier to manage complex programs where effi-
cient use of resources is required in order to achieve a time to
completion of studies comparable to those of high throughput
chemistry.
This work is motivated by the real world problem of pro-
viding insight from drug candidate data on a time scale that is
as short as possible. We demonstrate the use of a framework
– HTBAC, designed to support the aforementioned require-
ments of accurate and rapid drug binding affinity calculations.
HTBAC facilitates the execution of the numbers of simula-
tions while supporting the adaptive execution of algorithms.
Furthermore, HTBAC enables the selection of experimental
parameters during runtime, which can in principle optimize
the use of computational resources whilst producing results
with a target uncertainty.
II. METHODS AND MODELS
In this section we outline the computational methods em-
ployed and the physical system (drug candidates) studied. We
discuss how computational methods have been co-designed
with the software systems to support scalable approaches on
the largest supercomputers.
A. Binding Affinity Calculation Protocols
Computing accurate protein-drug binding affinities (also
known as binding free energies) requires a simulation tech-
nique which captures the chemical detail of the system. MD
simulations are the time dependent numerical integration of
the classical equations of motion for molecular systems. Ap-
plication of MD to atomistic models of proteins and their lig-
ands can be used to answer questions about the properties of
a specific system often more readily than experiments on the
actual system. Free-energy calculations in the framework of
MD simulations not only yield quantitative estimates of bind-
ing strength but also provide insights into the most important
interactions driving the process. Evidence from blind challenge
predictions and retrospective validation studies has suggested
that molecular dynamics (MD) can now achieve useful predic-
tive accuracy (1 kcal/mol) [5], [6]. This accuracy is sufficient
to greatly accelerate lead optimization [7].
Statistical mechanics provides the prescription for calcu-
lating such macroscopic quantities as ensemble averages of
microscopic states. Traditionally, these macroscopic proper-
ties have usually been calculated from the time average of a
single “long” duration trajectory. An intuitive and potentially
more time efficient method to capture the mixing dynamics re-
quired to describe an equilibrium thermodynamic state is the
use of an ensemble of separate trajectories. [8]
The major sources of error in free energy calculations are
the representation of the system chemistry encoded in the
forcefield used, finite sampling and the free energy estima-
tor. Protocols developed in the Coveney labs have obtained
accurate and precise results which successfully reproduce ex-
perimental binding free energies from a wide range of sys-
tems. [9], [3], [10], [11] Comparisons of results obtained for
a large set of sequences will provide valuable insights on the
importance of choices made in simulation and analysis for the
overall accuracy and predictive power of free energy calcula-
tions, and facilitate the refinement of our protocols.
Most methods for calculating binding affinities fit into
one of two broad classes; so called alchemical and endpoint
methodologies. Alchemical free energy calculations employ
unphysical (“alchemical”) intermediates to calculate changes
in free energies between two systems. It is common in these
methods to refer to a variable, λ, which describes the path
taken to transform one protein sequence (or ligand) into an-
other. Endpoint methods, as the name suggests, consider the
difference in energy between bound and unbound structures.
To obtain information on the differences in binding affinity
of different sequences for a panel of kinase inhibitors re-
quires a deployment of various strategies, incorporating both
alchemical and endpoint approaches. In this work we deploy
approaches from both of these classes.
1) Alchemical Protocol (TIES): Alchemical methods em-
ploy MD simulations of unphysical, alchemical intermediate
states that attenuate the interactions of the small molecule with
its environment. These alchemical intermediate states include
both the fully-interacting complex as well as replicas in which
the ligand does not interact with its environment, and allow
the total free energy of binding—including entropic and en-
thalpic contributions—to be efficiently computed. Typically,
the alchemical path between the states of interest is described
by a parameter, λ, which varies between 0 for the initial and
1 for the final state of the transformation of interest. Sampling
is then performed at a series of points along this path and the
gradient of the energy integrated to calculate the binding affin-
ity. Simulations conducted at a given λ value are said to be
sampling a λ window at that point.
The TIES (thermodynamic integration with enhanced sam-
pling) protocol, developed within the Coveney lab, employs
ensemble sampling at each λ window to yield reproducible,
accurate, and precise relative binding affinities. [3] Based on
the direct calculation of ensemble averages, it allows us to de-
termine statistically meaningful results along with complete
control of errors. As currently designed, TIES computes the
change in binding affinity between two related system (termed
‘relative binding affinities’).
2) Endpoint Protocol (ESMACS): Computationally
cheaper, but less rigorous methods, endpoint methods have
been used to directly compute the binding strength of a drug
to the target protein from MD simulations (as opposed to
differences in affinity).
We have developed an ensemble-based endpoint protocol
called ESMACS (enhanced sampling of molecular dynamics
with approximation of continuum solvent). The protocol is
built on the popular molecular mechanics Poisson–Boltzmann
surface area (MMPBSA) [12] method which makes a contin-
uum approximation for the aqueous solvent in order to obtain
results on practical timescales. Commonly, MMPBSA analy-
ses are performed on a single MD trajectory, or even a single
structure. We have demonstrated the lack of reproducibility
of such an approach in both HIV-1 protease and MHC sys-
tems, with calculations for the same protein-ligand combina-
tion, with identical initial structure and force field, shown to
produce binding affinities varying by up to 12 kcal/mol for
small ligands (flexible ligands can vary even more). [10] ES-
MACS employs MMPBSA to produce ensemble- based, con-
verged and reproducible, determinations of binding free en-
ergies (separate ligand and receptor trajectories can also be
used to account for adaptation energies). This provides a rapid
quantitative approach sensitive enough to determine changes
in binding free energies which differentiate susceptible and
resistant sequences (typically of the order of 2 kcal/mol).
B. BRD4 System
Initial coordinates for the protein-ligand system were taken
from a Protein Data Bank X-ray crystal structure (ID: 4BJX),
which contains BRD4 bound to one of the ligands investi-
gated in this study. The other 15 drugs were aligned to the
common THQ scaffold of the ligand in the crystal structure
to provide initial bound conformations. Preparation of simu-
lation input files were implemented using our automated tool,
BAC [13]. Preparation includes (i) parametrization of the com-
pounds (ii) solvation and neutralization of the system and
(iii) creation of MD engine configuration files. Parametrization
was performed with the widely used AMBER ff99SB-ILDN
force field for the protein, TIP3P for water molecules, and the
General Amber force field (GAFF) [14] for the ligands. Lig-
and geometries and point charges were produced using Gaus-
sian 03 at the Hartree–Fock level with 6-31G** basis functions
and the restrained electrostatic potential (RESP) module of the
AMBER package. All systems were solvated in orthorhombic
water boxes with a minimum extension from the protein of 14
A˚. The resulting systems contain approximately 40 thousand
atoms. Hybrid topologies for use in the TIES protocol were
created by combining the individual ligand parameters using
the process described in Bhati et al. [4].
III. COMPUTATIONAL CHALLENGES
As the nature of scientific inquiry and the applications to
support that inquiry evolve, there is a critical need to sup-
port the execution of scientific workflows on high-performance
computing (HPC) infrastructures. This poses three main chal-
lenges: (1) scaling the distributed execution of workflows; (2)
developing simple and usable workflow systems for HPC re-
sources; and (3) implementing runtime adaptivity.
A. Scalability
Applications composed of multiple tasks with dependences
that determine the order of their execution are referred to as
‘workflows’. Often times, the structure of the task dependen-
cies is simple and adheres to discernible patterns, even though
the individual tasks and their duration are non-trivially distinct.
Put together, it is a challenge to support the scalable execution
of workflows on HPC resources due to the existing system and
runtime software.
Currently, HPC software ecosystem mostly enables strong
and weak scaling of applications composed by a single simu-
lation that requires large amount of parallelism. This ecosys-
tem has instead limited support for the concurrent execution
of workflows, especially when composed of multiple hetero-
geneous tasks. Particularly limiting are the need to submit ev-
ery task to a batch system with long queue waiting time and
the limited amount of concurrency and flexibility offered by
machine and architecture-specific tools that enable bulk sub-
mission.
Multiple workflow systems have emerged in response to this
and other problems, each with its own strengths and unique
capability but also with specific problems and challenges. In
spite of the many successes of workflow systems, there is a
perceived high barrier-to-entry, integration overhead and lim-
ited flexibility.
B. Simplicity and Usability
Many commonly used workflow systems emerged from an
era when the support for distributed computing was fragile,
missing features and services. Consistently, workflow systems
had a monolithic design that included the end-to-end capa-
bilities needed to execute workflows on heterogeneous and
distributed cyberinfrastructures. Further, these workflow sys-
tems were typically designed to support large “big science”
projects such as those at the LHC [15] or LIGO [16]. There,
the same workflow was used by thousands of scientists over
many years, justifying the large overhead of developing appli-
cation workflows, and influencing programming models and
interfaces.
However as the nature, number and usage of workflows has
evolved so have the requirements: scale remains important but
only when delivered with the ability to prototype quickly and
flexibly. Further, new performance requirements arise from
the need to support concurrent execution of tasks with di-
verse requirements and relations. For example, when execut-
ing multiple homogeneous pipelines of heterogeneous tasks,
efficient resource utilization requires to ensure that individ-
ual pipelines have similar execution times, minimizing both
pipeline-to-pipeline and task-to-task runtime fluctuations.
Together, these factors challenge workflow systems de-
signed to mainly support specific use cases or ‘locked-in’
end-to-end executions. In the next Section, we discuss the
design and implementation of the RADICAL-Cybertools, a
set of software building blocks that can be easily composed
to design, implement and execute domain specific workflows
rapidly and at scale.
C. Adaptivity
Adaptive applications use intermediate data to enable better
fidelity in the modeling of complex phenomena that would oth-
erwise require unfeasible amount of computing time. Enabling
adaptive capability on HPC systems poses specific challenges
in expressibility, instantiation and implementation.
Adaptive applications requires to express both the applica-
tion workflow and how it should adapt depending on data gen-
erated at runtime. The former requires the description of the
application task graph, the latter methods to change this task
graph. These methods are called at the end of the execution
of a task and, depending on its output, determine the genera-
tion of a new portion of the graph. Abort, rollback, proceed,
forward and recovery are all examples of such methods [17].
Adaptation of the application at runtime depends on: (i)
propagation of adapted task graph to all components; (ii) con-
sistency of the state of task graph between different compo-
nents; and (iii) minimal overhead. Minimizing overheads is
particularly relevant as performing adaptive operations should
be irrelevant when compared to the time required by the tasks
execution.
IV. SOLUTION
RADICAL Cybertools (RCT), developed by The RADICAL
Lab, enables the efficient and dynamic execution of ensembles
on heterogeneous computing resources. Different from other
runtime systems, RCT decouples the workload execution and
resource management details from the expression of the appli-
cation, which significantly reduces the burden on the end user.
RCT has been used extensively to support biomolecular sci-
ences methods and algorithms, e.g., replica exchange, adaptive
sampling and high throughput binding affinity calculations.
Here we describe High Throughput Binding Affinity Calcu-
lator (HTBAC), which builds upon the RADICAL Cybertools,
as the framework solution to support the coordination of the
required scale of computations, thereby allowing us to employ
thousands of cores at a time.
Most benchmark evaluations of free energy protocols in the
literature look at only a small number of systems, drawing
inferences from tens or hundreds of runs. HTBAC facilitates
studies on unprecedented scales, with the number of systems
investigated an order of magnitude larger than published stud-
ies, which provides the opportunity to gain invaluable knowl-
edge on the domain of applicability of current MD technolo-
gies. In particular, we demonstrate the use of HTBAC to com-
pute the binding affinities of drugs to their target protein, us-
ing two simulation protocols with differing levels of rigor and
computational cost, ESMACS and TIES.
HTBAC is not limited to these protocols as additional pro-
tocols can be expressed and implemented easily with the HT-
BAC user-facing API, however for demonstration we focus
on these ensemble protocols HTBAC has demonstrated siz-
able execution and performance of the ESMACS [18] and
TIES [19] protocols on leadership class machines including
NCSA Blue Waters. For example, we demonstrated how HT-
BAC scales almost perfectly to hundreds of concurrent multi-
stage pipelines for the TIES protocol in Fig. 2.
Both ESMACS and TIES have been successfully used to
predict binding affinities quickly and accurately. In their stan-
dard non-adaptive forms TIES is approximately 2.5 times more
expensive than ESMACS. The ligands investigated here are
closely related so it could be expected that the greater accuracy
of TIES would be required to differentiate them. However, in
a drug design scenario many drug candidates would need to be
investigated meaning that optimizing the execution time while
retaining (or improving) accuracy is desirable. Given the very
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Fig. 2. Weak scaling properties of HTBAC. We investigate the weak scaling
of HTBAC as the ratio of the number of protocol instances to resources is kept
constant. Overheads of HTBAC framework (right), and RCT overhead (left)
and total execution time TTX (left) for experimental configurations investi-
gating the weak scaling of TIES. We ran two trials for each protocol instance
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Fig. 3. Adaptive quadrature of the function f(λ) = ∂U(λ)/∂λ in the in-
terval [0, 1] using the trapezoidal rule. The figures from left to right show
consecutive levels of recursion and bisection of intervals. The true integration
error is the difference between the interpolated function and the actual func-
tion (shaded area). If the error on an interval is larger than a threshold, the
interval is bisected.
large number of drug candidates, it is imperative to gain max-
imum insight into potential candidate compounds using time
and resources efficiently. This provides one clear motivation
for the use of adaptive methods which minimize the com-
pute time used whilst producing binding free energy estimates
meeting pre-defined quality criteria (such as convergence or
statistical uncertainty below a given threshold).
Typically, datasets will involve ligands with a wide range
of chemical properties which can impact not only the time to
convergence, but the type of sampling required to gain accurate
results. In general, there is no way to know before running
calculations exactly which setup of calculation is required for
a particular system. Even within closely related ligands, such
as the THQ based BRD4 ligands studied here, the ∂U/∂λ
curveλ integrated in TIES varies between physical systems
(drugs). Consequently, the number (or the exact location) of
the λ windows that will most impact the calculation are not
known a priori, and change between systems. As multiple
simulations must be run for each window, sampling with a
very high frequency is expensive and impractical. Furthermore,
adaptive placement of λ windows is likely to better capture
the shape of the ∂U/∂λ curve, leading to more accurate and
precise results for a given computational cost (see figure 3).
In order to support such investigations, in addition to being
scalable, HTBAC is enhanced to support flexible resource re-
allocations schemes where resources can be moved between
simulations run using different protocols or systems, for ex-
ample, when one calculation has converged whilst another has
not. This adaptability makes it easier to manage complex pro-
grams where efficient use of resources is required in order to
achieve a time to completion of studies comparable to those
of high throughput chemistry.
The novel contributions of HTBAC are: (i) Unprecedented
throughput: it allows the concurrent screening for drug bind-
ing affinities of multiple compounds at unprecedented scales,
both in the number of candidates and resources utilized; (ii)
Agile selection of different binding affinity protocols: HTBAC
supports inter-protocol adaptivity, leading to resources being
assigned at runtime to the “optimal” protocol (as determined
by accuracy for given computational cost); (iii) Support for
intra-protocol adaptivity, which provides the efficient execu-
tion of individual protocols.
A. Performance Metrics
TIES is rigorous but computationally expensive and has a
limited range of applicability; ESMACS is approximate but
can be employed across any set of ligands at lower compu-
tational cost. Both protocols are designed to simulate a large
range of mutations. A single protocol instance represents a
unique physical system. Each protocol instance contains a
pipeline which maps to a sequence of simulations steps which
include minimization, equilibration and production MD simu-
lation. These simulation pipelines are replicated, where repli-
cas differ only by their parameter configurations, namely ini-
tial velocities, which are randomly generated and assigned by
the MD engine at the start of execution. ESMACS consists
of 25 replicas i.e. 25 pipelines, while TIES consists of 13
λ windows, which are additional sampling parameters, and 5
replicas for a total of 65 pipelines. The additional pipelines in
TIES contribute to the greater computational cost. Both pro-
tocols run for a total of 6 ns simulation durations. ESMACS
produces 3.5 GB/system (24 MB/ns) while TIES produces 10
GB/system (24 MB/ns). Each simulation step in TIES and ES-
MACS requires 32 cores. Protocols run approximately 10-12
hours, depending on the physical system and the number of
timesteps provided by the user.
There are several measures of performance that are relevant.
The most pertinent is the weak scaling property which demon-
strates the ability of HTBAC to solve large number of drug
candidates in essentially the same amount of time (as the re-
sources increase). To this effect, we investigated weak scaling
behavior for screening sixteen drug candidates concurrently
using thousands of multi-stage pipelines on more than 32,000
cores on NCSA Blue Waters (as shown in Figure 2). Simi-
lar scaling has been demonstrated on other platforms such as
Titan for different protocols.
V. IMPACT OF SOLUTION
The flexibility provided by HTBAC to run adaptive work-
flows offers huge advantages scientifically. First, the intra-
protocol adaptivity allows the automated optimization of cal-
culations to ensure that results are obtained with known pre-
cision across systems which may exhibit very different behav-
ior (for example levels of ‘roughness’ in the ∂U/∂λ curve
in TIES). This has a significant impact of the reliability of
comparisons between runs. The ability to switch between pro-
tocols on the other hand offers a mechanism through which
‘cheaper’ approximate methods (such as ESMACS) can be
used to scan large regions of chemical space, whilst more ac-
curate and ‘expensive’ ones are employed to investigate areas
of specific interest (TIES). This maps directly onto processes
such as hit to lead optimization in drug discovery and could
be of particular use in investigating activity cliffs. This is a
phenomena where small chemical changes provide large dif-
ferences in drug efficacy. If changes are detected using an
approximate method it is important to verify that they come
from real chemical effects and not simply inaccuracies in the
computational algorithm employed.
The scale enabled by HTBAC also has an impact on the
potential for scientific discovery using free energy calculations.
Most studies in the literature are limited to the investigation
of tens of protein-ligand complexes. In order to establish the
validity of particular combinations of forcefield and simulation
protocol and quantify uncertainties much larger campaigns are
needed. Our ensemble has already provided evidence that the
variability in single runs is sufficient to swamp true differences
between systems of interest. The combined need for both large
numbers of systems and multiple repeats of each one produces
a requirement for middleware to manage huge numbers of
simulations.
HTBAC allows the concurrent screening for drug binding
affinities of multiple compounds at unprecedented scales, both
in the number of candidates and resources utilized. Specif-
ically, we investigated weak scaling behavior for screening
sixteen drug candidates concurrently using thousands of multi-
stage pipelines on more than 32,000 cores on NCSA Blue Wa-
ters. This permits a rapid time-to-solution that is essentially
invariant with respect to the calculation protocol, size of tar-
get system and number of ensemble simulations. In addition,
HTBAC enabled the adaptive execution of the TIES protocol
providing greater convergence (i.e., lower errors) for a given
amount of computational resources.
These developments fit into a wider vision in which the use
of flexible and responsive computational protocols produce ac-
curate, precise and reproducible estimates of the free energy
of binding with meaningful error bars. Not only would this al-
low for wider uptake of computational techniques in industrial
settings but opens up possibilities of using these technologies
in clinical decision support scenarios. By creating a ‘digital
twin’, where the target protein is based on the real patients
genetic sequence, a specific individuals response to different
treatments could be predicted.
VI. ANALYSIS OF SOLUTION
Our previous work deploying both ESMACS and TIES
has typically involved comparing 10 to 20 computed bind-
ing affinities. In the original BRD4 inhibitor study, conducted
in collaboration by UCL and GlaxoSmithKline [3], 16 drugs
were investigated. All drugs were studied using ESMACS and
12 TIES transformations were performed. The non-adaptive
protocols required approximately 10k and 25k core hours per
system for ESMACS and TIES respectively, for a total of
∼460k core hours for the whole study. Without HTBAC, each
system was run by hand. This scale of study is only appro-
priate for retrospective analysis showing the potential of the
methods involved. For in silico approaches to have a real im-
pact in industrial scenarios much larger numbers of systems
must be run, which is not practical without appropriate middle-
ware. HTBAC satisfies this need by providing a logically pro-
grammable interface which facilitates the routine of running
studies requiring sustained usage of millions of core hours per
day.
The drug design process involves the filtering of millions
of compounds to smaller number of ‘hits’ that bind the tar-
get protein and then further refinement to ‘leads’ that form
the basis of candidate drugs. Encapsulation of the ESMACS
and TIES protocols in HTBAC means that these protocols can
be efficiently applied to the middle and end of this process.
Adaptive functionality means that HTBAC can ensure efficient
use of the resources depending on the properties of the lig-
ands under investigation. This applies not only to the tuning
of calculations (e.g. the use of adaptive quadrature) but also at
a more strategic level where lower fidelity results could still
be used to inform resource reallocation. For example, if we
find that a particular ligand binds poorly compared to others
in a study we could halt those simulations even if the size of
the binding affinity difference had not fully converged. Care-
ful design of decision points in TIES, based on simulation
duration and λ window placement, could perhaps double the
number of predictions for a given computational cost.
Additionally, the flexibility supported by HTBAC provides
a platform to run the varied simulation campaigns needed to
stress test protocols and forcefields in order to further refine
our modeling approaches. HTBAC provides the functionality
needed to address various computation requirements presented
by drug screening campaigns, including facilitating the use of
models in which accuracy can be traded for a reduction in
computational cost; or inversely, by enabling tighter calcula-
tions with efficient resource utilization.
VII. IMPACT AND RESULT
We demonstrate how scalable, accurate and rapid binding
affinity calculation using HTBAC can enable effective clini-
cal decision making by showing performance and scale of the
number of drug candidates screened as a function of the num-
ber of core-hours. In addition, we show additional functionality
of HTBAC to enable the adaptivity of intra-protocol execution,
thereby providing greater convergence (i.e., lower errors) for
a given amount of computational resources. As such, HTBAC
advances binding affinity calculation to support scale and opti-
mize for time-to-insight for investigative drug screening com-
putational campaigns.
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